Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Clinical trial NCT02972034 · TERMINATED
Trial details
- NCT number
- NCT02972034
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-13
- Primary completion
- 2022-12-02
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.